RE:RE:As Long as the "Formal Valuation" is a minimum $18.50...I don't see this going back to $12s with interest rates where they are (the yield on Canadian 10 sovereigns is down to 3.17% from 4.25% when the first $20.5 offer was made). If you look at PLC, DNTL and the likes they have rallied substantially the last few weeks as investors started pricing a meaningful reduction in interest rates in 2024. If you combine that with the pharmacists shortage easing in 2H24, you have a very strong foundation for a major increase in adjusted and absolute EBITDA margins. As such, there might be a knee-jerk reaction to the deal falling apart, but that doesn't change the much improved outlook.